These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34862715)

  • 41. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials.
    Pin L; Villar SS; Dehbi HM
    Contemp Clin Trials; 2024 Jul; 142():107567. PubMed ID: 38729298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.
    Zhang Y; Guo B; Cao S; Zhang C; Zang Y
    Pharm Stat; 2022 Sep; 21(5):960-973. PubMed ID: 35332674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.
    Matsuura K; Sakamaki K; Honda J; Sozu T
    J Biopharm Stat; 2023 Sep; 33(5):639-652. PubMed ID: 36717962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
    Lin R; Yin G; Shi H
    Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study.
    Yamaguchi Y; Takeda K; Yoshida S; Maruo K
    J Biopharm Stat; 2024 May; 34(3):379-393. PubMed ID: 37114985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isotonic design for phase I cancer clinical trials with late-onset toxicities.
    Wages NA; Braun TM; Conaway MR
    J Biopharm Stat; 2023 May; 33(3):357-370. PubMed ID: 36606874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Escalation strategies for combination therapy Phase I trials.
    Sweeting MJ; Mander AP
    Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
    Li Z; Xu Z; Zhang A; Qi G; Li Z
    BMC Med Res Methodol; 2023 Mar; 23(1):57. PubMed ID: 36864387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incorporating historical information to improve phase I clinical trials.
    Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
    Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.